Protein kinases are critical players in intracellular signal transduction pathways and the etiology of many human diseases.  Over the last three decades, our understanding of this biological target class has grown such that there are now over 20 kinase inhibitors on the market for the treatment of cancer and now inflammatory disorders.  This presentation will describe the evolution of kinase drug discovery and development using three clinical candidate case histories to highlight key past milestones and future challenges.

Vignettes in kinase inhibitor drug discovery: Evolution of a drug target class

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.